Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Onco Targets Ther · 2014 · PMC4063862 · PMID 24966686

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

12 JAK2 V617F mutant cases showed a trend toward a higher platelet (3/6 >700×10 9 /L) and white blood cell count, as well as a moderate to marked increase in bone marrow cellularity.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.